{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:20:32Z","timestamp":1788402032172,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,2]]},"DOI":"10.7759\/cureus.115685","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:09:21Z","timestamp":1788401361000},"source":"Crossref","is-referenced-by-count":0,"title":["Mechanisms of Resistance to Targeted Therapy in Epidermal Growth Factor Receptor (EGFR)- and Anaplastic Lymphoma Kinase (ALK)-Mutated Non-small Cell Lung Cancer: Molecular Basis, Emerging Biomarkers, and Therapeutic Strategies"],"prefix":"10.7759","author":[{"given":"Sneha","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heena","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315056","article-title":"Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance","volume":"23","author":"Wu J","year":"2022","unstructured":"Wu J, Lin Z. Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance. Int J Mol Sci. 2022, 23:15056. 10.3390\/ijms232315056","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2452","article-title":"Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer","volume":"24","author":"McCoach CE","year":"2018","unstructured":"McCoach CE, Le AT, Gowan K, et al.. Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer. Clin Cancer Res. 2018, 24:3334-47. 10.1158\/1078-0432.CCR-17-2452","journal-title":"Clin Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020504","article-title":"Mechanisms of acquired resistance and tolerance to EGFR targeted therapy in non-small cell lung cancer","volume":"15","author":"Chhouri H","year":"2023","unstructured":"Chhouri H, Alexandre D, Grumolato L. Mechanisms of acquired resistance and tolerance to EGFR targeted therapy in non-small cell lung cancer. Cancers (Basel). 2023, 15:504. 10.3390\/cancers15020504","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti A","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019, 121:725-37. 10.1038\/s41416-019-0573-8","journal-title":"Br J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-022-00107-x","article-title":"Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer","volume":"3","author":"Wang Z","year":"2022","unstructured":"Wang Z, Xing Y, Li B, Li X, Liu B, Wang Y. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. Mol Biomed. 2022, 3:42. 10.1186\/s43556-022-00107-x","journal-title":"Mol Biomed"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143337","article-title":"Resistance to TKIs in EGFR-mutated non-small cell lung cancer: from mechanisms to new therapeutic strategies","volume":"14","author":"Koulouris A","year":"2022","unstructured":"Koulouris A, Tsagkaris C, Corriero AC, Metro G, Mountzios G. Resistance to TKIs in EGFR-mutated non-small cell lung cancer: from mechanisms to new therapeutic strategies. Cancers (Basel). 2022, 14:3337. 10.3390\/cancers14143337","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.02.006","article-title":"Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies","volume":"65","author":"Lim SM","year":"2018","unstructured":"Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Treat Rev. 2018, 65:1-10. 10.1016\/j.ctrv.2018.02.006","journal-title":"Cancer Treat Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0777-1","article-title":"Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer","volume":"17","author":"Wu SG","year":"2018","unstructured":"Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018, 17:38. 10.1186\/s12943-018-0777-1","journal-title":"Mol Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112613","article-title":"Early steps of resistance to targeted therapies in non-small-cell lung cancer","volume":"14","author":"Delahaye C","year":"2022","unstructured":"Delahaye C, Figarol S, Pradines A, Favre G, Mazieres J, Calvayrac O. Early steps of resistance to targeted therapies in non-small-cell lung cancer. Cancers (Basel). 2022, 14:2613. 10.3390\/cancers14112613","journal-title":"Cancers (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061604","article-title":"The resistance to EGFR-TKIs in non-small cell lung cancer: from molecular mechanisms to clinical application of new therapeutic strategies","volume":"15","author":"Laface C","year":"2023","unstructured":"Laface C, Maselli FM, Santoro AN, et al.. The resistance to EGFR-TKIs in non-small cell lung cancer: from molecular mechanisms to clinical application of new therapeutic strategies. Pharmaceutics. 2023, 15:1604. 10.3390\/pharmaceutics15061604","journal-title":"Pharmaceutics"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2021.5270","article-title":"Mechanisms and management of 3rd\u2011generation EGFR\u2011TKI resistance in advanced non\u2011small cell lung cancer (Review)","volume":"59","author":"He J","year":"2021","unstructured":"He J, Huang Z, Han L, Gong Y, Xie C. Mechanisms and management of 3rd\u2011generation EGFR\u2011TKI resistance in advanced non\u2011small cell lung cancer (Review). Int J Oncol. 2021, 59:10.3892\/ijo.2021.5270","journal-title":"Int J Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki J","year":"2023","unstructured":"Chmielecki J, Gray JE, Cheng Y, et al.. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nat Commun. 2023, 14:1070. 10.1038\/s41467-023-35961-y","journal-title":"Nat Commun"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104295","article-title":"The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced non-small cell lung cancer patients: the challenge is open for new therapeutic strategies","volume":"196","author":"Ferro A","year":"2024","unstructured":"Ferro A, Marinato GM, Mulargiu C, Marino M, Pasello G, Guarneri V, Bonanno L. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced non-small cell lung cancer patients: the challenge is open for new therapeutic strategies. Crit Rev Oncol Hematol. 2024, 196:104295. 10.1016\/j.critrevonc.2024.104295","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.05.011","article-title":"Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies","volume":"170","author":"Johnson M","year":"2022","unstructured":"Johnson M, Garassino MC, Mok T, Mitsudomi T. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer. 2022, 170:41-51. 10.1016\/j.lungcan.2022.05.011","journal-title":"Lung Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194926","article-title":"Molecular mechanism of EGFR-TKI resistance in EGFR-mutated non-small cell lung cancer: application to biological diagnostic and monitoring","volume":"13","author":"Reita D","year":"2021","unstructured":"Reita D, Pabst L, Pencreach E, et al.. Molecular mechanism of EGFR-TKI resistance in EGFR-mutated non-small cell lung cancer: application to biological diagnostic and monitoring. Cancers (Basel). 2021, 13:4926. 10.3390\/cancers13194926","journal-title":"Cancers (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126489","article-title":"EGFR-mutated non-small cell lung cancer and resistance to immunotherapy: role of the tumor microenvironment","volume":"23","author":"Madeddu C","year":"2022","unstructured":"Madeddu C, Donisi C, Liscia N, Lai E, Scartozzi M, Macci\u00f2 A. EGFR-mutated non-small cell lung cancer and resistance to immunotherapy: role of the tumor microenvironment. Int J Mol Sci. 2022, 23:6489. 10.3390\/ijms23126489","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0736","article-title":"Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing","volume":"15","author":"Kohsaka S","year":"2019","unstructured":"Kohsaka S, Petronczki M, Solca F, Maemondo M. Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. Future Oncol. 2019, 15:637-52. 10.2217\/fon-2018-0736","journal-title":"Future Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03828-8","article-title":"Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy","volume":"147","author":"Zhao Y","year":"2021","unstructured":"Zhao Y, Wang H, He C. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy. J Cancer Res Clin Oncol. 2021, 147:3653-64. 10.1007\/s00432-021-03828-8","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1795614","article-title":"Non-small cell lung cancer after EGFR-TKI resistance: from drug resistance mechanisms to precision interventions","volume":"17","author":"Wang Z","year":"2026","unstructured":"Wang Z, Song Y, Wang A, Liu B. Non-small cell lung cancer after EGFR-TKI resistance: from drug resistance mechanisms to precision interventions. Front Pharmacol. 2026, 17:1795614. 10.3389\/fphar.2026.1795614","journal-title":"Front Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1366260","article-title":"Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges","volume":"15","author":"Xiang Y","year":"2024","unstructured":"Xiang Y, Liu X, Wang Y, et al.. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges. Front Immunol. 2024, 15:1366260. 10.3389\/fimmu.2024.1366260","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu K","year":"2022","unstructured":"Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022, 15:173. 10.1186\/s13045-022-01391-4","journal-title":"J Hematol Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki J","year":"2023","unstructured":"Chmielecki J, Mok T, Wu YL, et al.. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nat Commun. 2023, 14:1071. 10.1038\/s41467-023-35962-x","journal-title":"Nat Commun"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104407","article-title":"Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance","volume":"30","author":"Roberts SK","year":"2025","unstructured":"Roberts SK, Galgadas I, Clarke DT, Zanetti-Domingues LC, Gervasio FL, Martin-Fernandez ML. Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance. Drug Discov Today. 2025, 30:104407. 10.1016\/j.drudis.2025.104407","journal-title":"Drug Discov Today"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1387345","article-title":"Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives","volume":"14","author":"Zhang H","year":"2024","unstructured":"Zhang H, Zhang Y, Zhu Y, Dong T, Liu Z. Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives. Front Oncol. 2024, 14:1387345. 10.3389\/fonc.2024.1387345","journal-title":"Front Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201707945","article-title":"Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer","volume":"10","author":"Tsui DW","year":"2018","unstructured":"Tsui DW, Murtaza M, Wong AS, et al.. Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer. EMBO Mol Med. 2018, 10:10.15252\/emmm.201707945","journal-title":"EMBO Mol Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241234504","article-title":"Molecular features and clinical outcomes of EGFR-mutated, MET-amplified non-small-cell lung cancer after resistance to dual-targeted therapy","volume":"16","author":"Fang MM","year":"2024","unstructured":"Fang MM, Cheng JT, Chen YQ, et al.. Molecular features and clinical outcomes of EGFR-mutated, MET-amplified non-small-cell lung cancer after resistance to dual-targeted therapy. Ther Adv Med Oncol. 2024, 16:17588359241234504. 10.1177\/17588359241234504","journal-title":"Ther Adv Med Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122987","article-title":"Targeting HSF1 as a therapeutic strategy for multiple mechanisms of EGFR inhibitor resistance in EGFR mutant non-small-cell lung cancer","volume":"13","author":"Lee S","year":"2021","unstructured":"Lee S, Jung J, Lee YJ, et al.. Targeting HSF1 as a therapeutic strategy for multiple mechanisms of EGFR inhibitor resistance in EGFR mutant non-small-cell lung cancer. Cancers (Basel). 2021, 13:2987. 10.3390\/cancers13122987","journal-title":"Cancers (Basel)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1451230","article-title":"Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials","volume":"14","author":"Yu L","year":"2024","unstructured":"Yu L, Yang R, Long Z, Tao Q, Liu B. Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials. Front Oncol. 2024, 14:1451230. 10.3389\/fonc.2024.1451230","journal-title":"Front Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad052","article-title":"Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance","volume":"53","author":"Araki T","year":"2023","unstructured":"Araki T, Kanda S, Horinouchi H, Ohe Y. Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance. Jpn J Clin Oncol. 2023, 53:547-61. 10.1093\/jjco\/hyad052","journal-title":"Jpn J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052042","article-title":"Drug resistance in late-stage epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer patients after first-line treatment with tyrosine kinase inhibitors","volume":"26","author":"Lee CY","year":"2025","unstructured":"Lee CY, Lee SW, Hsu YC. Drug resistance in late-stage epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer patients after first-line treatment with tyrosine kinase inhibitors. Int J Mol Sci. 2025, 26:2042. 10.3390\/ijms26052042","journal-title":"Int J Mol Sci"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.713530","article-title":"The resistance mechanisms and treatment strategies for ALK-rearranged non-small cell lung cancer","volume":"11","author":"Pan Y","year":"2021","unstructured":"Pan Y, Deng C, Qiu Z, Cao C, Wu F. The resistance mechanisms and treatment strategies for ALK-rearranged non-small cell lung cancer. Front Oncol. 2021, 11:713530. 10.3389\/fonc.2021.713530","journal-title":"Front Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2359","article-title":"Amplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors","volume":"77","author":"Nukaga S","year":"2017","unstructured":"Nukaga S, Yasuda H, Tsuchihara K, et al.. Amplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors. Cancer Res. 2017, 77:2078-89. 10.1158\/0008-5472.CAN-16-2359","journal-title":"Cancer Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107123","article-title":"PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: clinical challenges and opportunities","volume":"202","author":"Liu X","year":"2024","unstructured":"Liu X, Mei W, Zhang P, Zeng C. PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: clinical challenges and opportunities. Pharmacol Res. 2024, 202:107123. 10.1016\/j.phrs.2024.107123","journal-title":"Pharmacol Res"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.09.019","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study","volume":"137","author":"Mehlman C","year":"2019","unstructured":"Mehlman C, Cadranel J, Rousseau-Bussac G, et al.. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study. Lung Cancer. 2019, 137:149-56. 10.1016\/j.lungcan.2019.09.019","journal-title":"Lung Cancer"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae312","article-title":"COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer","volume":"30","author":"Mehlman C","year":"2025","unstructured":"Mehlman C, Swalduz A, Monnet I, et al.. COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer. Oncologist. 2025, 30:10.1093\/oncolo\/oyae312","journal-title":"Oncologist"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1652213","article-title":"Dissecting the immune evasion and therapeutic resistance mechanisms in EGFR\/TP53 co-mutated non-small cell lung cancer: implications for targeted and immunotherapy strategies","volume":"16","author":"Shi H","year":"2025","unstructured":"Shi H, Xu K, Kong X, et al.. Dissecting the immune evasion and therapeutic resistance mechanisms in EGFR\/TP53 co-mutated non-small cell lung cancer: implications for targeted and immunotherapy strategies. Front Immunol. 2025, 16:1652213. 10.3389\/fimmu.2025.1652213","journal-title":"Front Immunol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051321","article-title":"Direct targeting KRAS mutation in non-small cell lung cancer: focus on resistance","volume":"14","author":"Reita D","year":"2022","unstructured":"Reita D, Pabst L, Pencreach E, et al.. Direct targeting KRAS mutation in non-small cell lung cancer: focus on resistance. Cancers (Basel). 2022, 14:1321. 10.3390\/cancers14051321","journal-title":"Cancers (Basel)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.70029","article-title":"MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer","volume":"19","author":"Hu J","year":"2025","unstructured":"Hu J, Ding N, Xu X, et al.. MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer. Mol Oncol. 2025, 19:2715-29. 10.1002\/1878-0261.70029","journal-title":"Mol Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01479","article-title":"Targeting immunometabolism mediated by CD73 pathway in EGFR-mutated non-small cell lung cancer: a new hope for overcoming immune resistance","volume":"11","author":"Passarelli A","year":"2020","unstructured":"Passarelli A, Aieta M, Sgambato A, Gridelli C. Targeting immunometabolism mediated by CD73 pathway in EGFR-mutated non-small cell lung cancer: a new hope for overcoming immune resistance. Front Immunol. 2020, 11:1479. 10.3389\/fimmu.2020.01479","journal-title":"Front Immunol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107249","article-title":"The significance of co-mutations in EGFR-mutated non-small cell lung cancer: optimizing the efficacy of targeted therapies?","volume":"181","author":"Pezzuto F","year":"2023","unstructured":"Pezzuto F, Hofman V, Bontoux C, Fortarezza F, Lunardi F, Calabrese F, Hofman P. The significance of co-mutations in EGFR-mutated non-small cell lung cancer: optimizing the efficacy of targeted therapies?. Lung Cancer. 2023, 181:107249. 10.1016\/j.lungcan.2023.107249","journal-title":"Lung Cancer"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-1515","article-title":"Eradicating drug-tolerant persister cells in EGFR-mutated non-small cell lung cancer by targeting TROP2 with CAR-T cellular therapy","volume":"15","author":"Baldacci S","year":"2025","unstructured":"Baldacci S, Brea EJ, Facchinetti F, et al.. Eradicating drug-tolerant persister cells in EGFR-mutated non-small cell lung cancer by targeting TROP2 with CAR-T cellular therapy. Cancer Discov. 2025, 15:2235-50. 10.1158\/2159-8290.CD-24-1515","journal-title":"Cancer Discov"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.1453","article-title":"Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib","volume":"19","author":"Rotow JK","year":"2024","unstructured":"Rotow JK, Lee JK, Madison RW, Oxnard GR, J\u00e4nne PA, Schrock AB. Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib. J Thorac Oncol. 2024, 19:227-39. 10.1016\/j.jtho.2023.09.1453","journal-title":"J Thorac Oncol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102664","article-title":"The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer","volume":"122","author":"Ciardiello F","year":"2024","unstructured":"Ciardiello F, Hirsch FR, Pirker R, Felip E, Valencia C, Smit EF. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer. Cancer Treat Rev. 2024, 122:102664. 10.1016\/j.ctrv.2023.102664","journal-title":"Cancer Treat Rev"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103935","article-title":"Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors","volume":"9","author":"Li Y","year":"2024","unstructured":"Li Y, Zeng H, Qi C, et al.. Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors. ESMO Open. 2024, 9:103935. 10.1016\/j.esmoop.2024.103935","journal-title":"ESMO Open"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.06.011","article-title":"Actionability of on-target ALK resistance mutations in patients with non-small cell lung cancer: local experience and review of the literature","volume":"23","author":"Koopman B","year":"2022","unstructured":"Koopman B, Groen HJ, Schuuring E, et al.. Actionability of on-target ALK resistance mutations in patients with non-small cell lung cancer: local experience and review of the literature. Clin Lung Cancer. 2022, 23:e104-15. 10.1016\/j.cllc.2021.06.011","journal-title":"Clin Lung Cancer"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.860563","article-title":"TP53 co-mutations in advanced EGFR-mutated non-small cell lung cancer: prognosis and therapeutic strategy for cancer therapy","volume":"12","author":"Liu S","year":"2022","unstructured":"Liu S, Yu J, Zhang H, Liu J. TP53 co-mutations in advanced EGFR-mutated non-small cell lung cancer: prognosis and therapeutic strategy for cancer therapy. Front Oncol. 2022, 12:860563. 10.3389\/fonc.2022.860563","journal-title":"Front Oncol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092475","article-title":"FGFR fusions as an acquired resistance mechanism following treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) and a suggested novel target in advanced non-small cell lung cancer (aNSCLC)","volume":"11","author":"Raphael A","year":"2022","unstructured":"Raphael A, Dudnik E, Hershkovitz D, et al.. FGFR fusions as an acquired resistance mechanism following treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) and a suggested novel target in advanced non-small cell lung cancer (aNSCLC). J Clin Med. 2022, 11:2475. 10.3390\/jcm11092475","journal-title":"J Clin Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00704","article-title":"Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer","volume":"65","author":"Eno MS","year":"2022","unstructured":"Eno MS, Brubaker JD, Campbell JE, et al.. Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer. J Med Chem. 2022, 65:9662-77. 10.1021\/acs.jmedchem.2c00704","journal-title":"J Med Chem"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115917","article-title":"Targeted therapies for EGFR exon 20 insertion mutation in non-small-cell lung cancer","volume":"25","author":"Seo D","year":"2024","unstructured":"Seo D, Lim JH. Targeted therapies for EGFR exon 20 insertion mutation in non-small-cell lung cancer. Int J Mol Sci. 2024, 25:5917. 10.3390\/ijms25115917","journal-title":"Int J Mol Sci"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2025.2536006","article-title":"Overcoming triple mutant EGFR-tyrosine kinase barriers in the therapeutics of non-small cell lung cancer: a patent review on fourth-generation inhibitors (2017-2024)","volume":"35","author":"Nagpure NR","year":"2025","unstructured":"Nagpure NR, Patel HM. Overcoming triple mutant EGFR-tyrosine kinase barriers in the therapeutics of non-small cell lung cancer: a patent review on fourth-generation inhibitors (2017-2024). Expert Opin Ther Pat. 2025, 35:963-82. 10.1080\/13543776.2025.2536006","journal-title":"Expert Opin Ther Pat"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01082-8","article-title":"Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer","volume":"21","author":"Li Y","year":"2023","unstructured":"Li Y, Mao T, Wang J, et al.. Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer. Cell Commun Signal. 2023, 21:71. 10.1186\/s12964-023-01082-8","journal-title":"Cell Commun Signal"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0887-2","article-title":"Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer","volume":"38","author":"Raoof S","year":"2019","unstructured":"Raoof S, Mulford IJ, Frisco-Cabanos H, et al.. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene. 2019, 38:6399-413. 10.1038\/s41388-019-0887-2","journal-title":"Oncogene"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1845547","article-title":"Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance","volume":"17","author":"Niu J","year":"2026","unstructured":"Niu J, Jing W, Liu Z, Si Y, Liu Z. Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance. Front Immunol. 2026, 17:1845547. 10.3389\/fimmu.2026.1845547","journal-title":"Front Immunol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-024-01221-2","article-title":"Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer","volume":"56","author":"Park W","year":"2024","unstructured":"Park W, Wei S, Xie CL, et al.. Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer. Exp Mol Med. 2024, 56:1137-49. 10.1038\/s12276-024-01221-2","journal-title":"Exp Mol Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2025.122","article-title":"New advances in understanding the mechanisms and treatment challenges of ALK-targeted therapy resistance in lung cancer","volume":"8","author":"Long M","year":"2025","unstructured":"Long M, Peng S, Wen Q, et al.. New advances in understanding the mechanisms and treatment challenges of ALK-targeted therapy resistance in lung cancer. Cancer Drug Resist. 2025, 8:43. 10.20517\/cdr.2025.122","journal-title":"Cancer Drug Resist"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05456-5","article-title":"EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1\/2-p90RSK-TGF-\u03b2 axis in non-small cell lung cancer","volume":"22","author":"Huang H","year":"2024","unstructured":"Huang H, Zhu X, Yu Y, Li Z, Yang Y, Xia L, Lu S. EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1\/2-p90RSK-TGF-\u03b2 axis in non-small cell lung cancer. J Transl Med. 2024, 22:653. 10.1186\/s12967-024-05456-5","journal-title":"J Transl Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1177\/10732748241292782","article-title":"Targeting EGFR exon 20 insertion mutations in non-small-cell lung cancer: changes in treatment strategies are coming","volume":"31","author":"Liu H","year":"2024","unstructured":"Liu H, Qin J, Qian X. Targeting EGFR exon 20 insertion mutations in non-small-cell lung cancer: changes in treatment strategies are coming. Cancer Control. 2024, 31:10732748241292782. 10.1177\/10732748241292782","journal-title":"Cancer Control"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09734-5","article-title":"AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy","volume":"10","author":"Bertran-Alamillo J","year":"2019","unstructured":"Bertran-Alamillo J, Cattan V, Schoumacher M, et al.. AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. Nat Commun. 2019, 10:1812. 10.1038\/s41467-019-09734-5","journal-title":"Nat Commun"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients","volume":"24","author":"Yang Z","year":"2018","unstructured":"Yang Z, Yang N, Ou Q, et al.. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin Cancer Res. 2018, 24:3097-107. 10.1158\/1078-0432.CCR-17-2310","journal-title":"Clin Cancer Res"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.2147\/TACG.S531337","article-title":"Differential responses to targeted therapies in non-small cell lung cancer: a comparative analysis of outcomes in patients with single EGFR mutation and concurrent gene alterations","volume":"18","author":"Le LT","year":"2025","unstructured":"Le LT, Nguyen NV, Trinh HL, et al.. Differential responses to targeted therapies in non-small cell lung cancer: a comparative analysis of outcomes in patients with single EGFR mutation and concurrent gene alterations. Appl Clin Genet. 2025, 18:153-64. 10.2147\/TACG.S531337","journal-title":"Appl Clin Genet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/525295-mechanisms-of-resistance-to-targeted-therapy-in-epidermal-growth-factor-receptor-egfr--and-anaplastic-lymphoma-kinase-alk-mutated-non-small-cell-lung-cancer-molecular-basis-emerging-biomarkers-and-therapeutic-strategies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:09:22Z","timestamp":1788401362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/525295-mechanisms-of-resistance-to-targeted-therapy-in-epidermal-growth-factor-receptor-egfr--and-anaplastic-lymphoma-kinase-alk-mutated-non-small-cell-lung-cancer-molecular-basis-emerging-biomarkers-and-therapeutic-strategies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":60,"URL":"https:\/\/doi.org\/10.7759\/cureus.115685","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}